Remy Durand - Alpine Immune Chief Officer
| ALPNDelisted Stock | USD 12.37 0.23 1.83% |
Insider
Remy Durand is Chief Officer of Alpine Immune Sciences
| Age | 39 |
| Phone | 206 788 4545 |
| Web | https://www.alpineimmunesciences.com |
Remy Durand Latest Insider Activity
Tracking and analyzing the buying and selling activities of Remy Durand against Alpine Immune stock is an integral part of due diligence when investing in Alpine Immune. Remy Durand insider activity provides valuable insight into whether Alpine Immune is net buyers or sellers over its current business cycle. Note, Alpine Immune insiders must abide by specific rules, including filing SEC forms every time they buy or sell Alpine Immune'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Remy Durand over six months ago Disposition of 78000 shares by Remy Durand of Alpine Immune at 18.33 subject to Rule 16b-3 |
Alpine Immune Management Efficiency
The company has return on total asset (ROA) of (0.101) % which means that it has lost $0.101 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1467) %, meaning that it created substantial loss on money invested by shareholders. Alpine Immune's management efficiency ratios could be used to measure how well Alpine Immune manages its routine affairs as well as how well it operates its assets and liabilities.Alpine Immune Sciences currently holds 9.91 M in liabilities with Debt to Equity (D/E) ratio of 0.17, which may suggest the company is not taking enough advantage from borrowing. Alpine Immune Sciences has a current ratio of 2.7, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Alpine Immune's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Man MBA | Adagene | 48 | |
| Saptarsi MD | Tenaya Therapeutics | N/A | |
| Dawn Kalmar | Stoke Therapeutics | 47 | |
| Mark Vignola | Terns Pharmaceuticals | 47 | |
| FAAD MBA | AnaptysBio | 47 | |
| Dennis Mulroy | AnaptysBio | 70 | |
| Bruce Keyt | IGM Biosciences | 71 | |
| Gina Mazzariello | Amylyx Pharmaceuticals | 53 | |
| Tom Holmes | Amylyx Pharmaceuticals | N/A | |
| Joshua Cohen | Amylyx Pharmaceuticals | 34 | |
| Jc MD | Adagene | 60 | |
| KeeHong Kim | Tenaya Therapeutics | 59 | |
| Isabel Aznarez | Stoke Therapeutics | 53 | |
| MD MBA | Amylyx Pharmaceuticals | 63 | |
| Jorge Silva | MoonLake Immunotherapeutics | 47 | |
| Deepak MD | Tenaya Therapeutics | 59 | |
| Eric Rojas | Stoke Therapeutics | N/A | |
| Erick MD | Acrivon Therapeutics, Common | 67 | |
| Eric Devroe | Acrivon Therapeutics, Common | 46 | |
| James MBA | Amylyx Pharmaceuticals | 58 | |
| FACP MD | IGM Biosciences | 63 | |
Management Performance
| Return On Equity | -0.15 | |||
| Return On Asset | -0.1 |
Alpine Immune Sciences Leadership Team
Elected by the shareholders, the Alpine Immune's board of directors comprises two types of representatives: Alpine Immune inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Alpine. The board's role is to monitor Alpine Immune's management team and ensure that shareholders' interests are well served. Alpine Immune's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Alpine Immune's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Temre Johnson, Head Communications | ||
| Remy Durand, Chief Officer | ||
| Andrew MD, Chief Officer | ||
| Paul Rickey, CFO, Senior Vice President Secretary | ||
| Stanford MD, President Development | ||
| Wayne Gombotz, Chief Officer | ||
| Mitchell MD, Executive CEO | ||
| Pamela Holland, VP Research | ||
| Wolfgang MD, Chief Officer | ||
| Christina Yi, Chief Officer |
Alpine Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Alpine Immune a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.15 | |||
| Return On Asset | -0.1 | |||
| Profit Margin | (0.65) % | |||
| Operating Margin | (3.23) % | |||
| Current Valuation | 4.16 B | |||
| Shares Outstanding | 68.6 M | |||
| Shares Owned By Insiders | 4.60 % | |||
| Shares Owned By Institutions | 99.46 % | |||
| Number Of Shares Shorted | 3.89 M | |||
| Price To Earning | (32.69) X |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Other Consideration for investing in Alpine Stock
If you are still planning to invest in Alpine Immune Sciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Alpine Immune's history and understand the potential risks before investing.
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |